Diabetes
Conference Coverage
Diabetes tied to risk of long COVID, too
Roughly 43% of studies in a literature review identified diabetes as a risk factor for postacute sequelae of COVID-19.
Conference Coverage
Exercise of any type boosts type 1 diabetes time in range
Aerobic, interval, and resistance training all were significantly associated with improved glucose time in range, compared to no exercise.
Conference Coverage
‘DIY’ artificial pancreas systems found to be safe, effective: CREATE trial
So-called “do it yourself” artificial pancreas systems predate commercially available automated insulin delivery systems, but many people with...
Conference Coverage
Prediabetes is linked independently to myocardial infarction
A history of prediabetes is predictor of MI independent of any other risk factor, suggesting that screening efforts should increase.
Conference Coverage
Avexitide promising for hypoglycemia after weight-loss surgery
The GLP-1 receptor antagonist reduced all levels of hypoglycemia, by different measures, and in patients who had undergone different bariatric...
Conference Coverage
SGLT2 inhibitors cut AFib risk in real-word analysis
Observational data add to a growing link between SGLT2 inhibitor treatment and atrial fibrillation prevention in people with type 2 diabetes.
News
New guideline for in-hospital care of diabetes says use CGMs
Patients with diabetes or newly recognized hyperglycemia get admitted to every patient service in the hospital, and their glycemic management can...
Conference Coverage
Self-injury and suicide ‘all too common’ in type 1 diabetes
“With a multipronged approach to awareness, education, and identification, we have the opportunity to intervene on the link between suicide and...
News
ADA updates on finerenone, SGLT2 inhibitors, and race-based eGFR
ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2...
Conference Coverage
Stem cell transplants could be ‘transformational’ in type 1 diabetes
A second patient who received Vertex’s VX-880 has experienced glycemic improvements, while the first one is completely insulin independent.